Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 801–900 of 1,000
What's new in the other general journals
Tonks, A. (2006) · BMJ · doi:10.1136/bmj.332.7536.289 · Cited by 6
Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors
Ruixo, J. J. P., Doshi, S., Sohn, W. Y., & Chow, A. T. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.388 · Cited by 5
Paul, T. V., Garg, B., Kapoor, N., Patil, V., Kachnerkar, N. I., Shembalkar, J., Purohit, S., Maheshwari, S., Maheshwari, S., Yadav, A. K., et al. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0772 · Cited by 5
Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma
Massat, B., Stiff, P. J., Esmail, F., Mariotti, E. G., & Hagen, P. A. (2025) · Cells · doi:10.3390/cells14161263 · Cited by 5
Jiang, H., Zhang, Y., Luo, Z., Tang, X., 赫一佑, & Hao, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1808488 · Cited by 7
Burns, R. B., Smith, C. C., Shmerling, R. H., & Tess, A. V. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2548 · Cited by 5
Clarke, B. L. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.04.014 · Cited by 5
Anti-Cancer (Novel Agents): A Review
Sravanthi, Mayure, V., Finny, G. J., & Meher, C. (2014) · Pharmatutor · Cited by 5
Hoffman, V., Xue, F., Gardstein, B. M., Skerry, K., Critchlow, C. W., & Enger, C. L. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3680 · Cited by 5
Treatment of autoimmune diseases: A systems biology approach
Martínez‐Forero, I., Ibarrola, A. S., & Villoslada, P. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2007.08.005 · Cited by 5
The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis
VARENNA, M., & Gatti, D. (2011) · Reumatismo · doi:10.4081/reumatismo.2010.163 · Cited by 8
Preventing metastases to bone: Denosumab or bisphosphonates?
Nanes, M. S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.71 · Cited by 5
Evaluation and Medical Management of Fragility Fractures of the Upper Extremity
Gutowski, C. J., & Ilyas, A. M. (2014) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.12.005 · Cited by 5
The FREEDOM trial: Is family medicine ready for biologic therapies?
Bell, A., & Bell, B. R. (2011) · Europe PMC (PubMed Central) · Cited by 5
Boyanov, M., Shinkov, A. D., Psachoulia, E., Intorcia, M., & Petkova, R. T. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0159-3 · Cited by 5
Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
Kaneko, K., Shikano, K., Kawazoe, M., Kawai, S., & Nanki, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8560-21 · Cited by 5
Computed tomography density changes of bone metastases after concomitant denosumab
Mallio, C. A., Greco, F., Gaudino, F., Zobel, B. B., & Quattrocchi, C. C. (2023) · Skeletal Radiology · doi:10.1007/s00256-023-04326-3 · Cited by 5
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., Taniguchi, Y., Morinaga, S., Asano, Y., Nojima, T., & Tsuchiya, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1230074 · Cited by 5
Utilization of bone impedance for age estimation in postmortem cases
Ishikawa, N., Suganami, H., Nishida, A., Miyamori, D., Kakiuchi, Y., Yamada, N., Kim, W., Kubo, T., & Ikegaya, H. (2015) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2015.09.006 · Cited by 5
Twist on a classic: vitamin D and hypercalcaemia of malignancy
Osorio, J. C., Jones, M. G., Schatz-Siemers, N., & Tang, S. J. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-220819 · Cited by 5
Tripto‐Shkolnik, L., Liel, Y., Yekutiel, N., & Goldshtein, I. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1368-4218 · Cited by 5
Bitar, Z. I., Hajjiah, A., Maadarani, O. S., Elzoueiry, M. M., Gohar, M. R., Abdelfatah, M., & Alabdali, F. (2024) · Nutrition and Metabolic Insights · doi:10.1177/11786388231223604 · Cited by 5
Prevention and treatment of postmenopausal osteoporosis
Neuprez, A., & Reginster, J. (2010) · doi:10.1007/978-1-907673-28-3_4 · Cited by 5
Zoledronic acid for treatment of Paget's disease of bone
Devogelaer, J., & Manicourt, D. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.16.2863 · Cited by 5
Hiperparatiroidismo primario normocalcémico: un problema en aumento
Diaz‐Guerra, G. M., Iglesias, S. G., & Carranza, F. H. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.09.025 · Cited by 5
Over-suppression of bone turnover: Does it exist?
Compston, J. E. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0014-0 · Cited by 5
Barrio, P., Hidalgo, D., & Udina, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.014 · Cited by 5
Newer Therapies for Osteoporosis
Palaniswamy, C., Selvaraj, D. R., Rao, V., & Patel, U. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181a6ee1c · Cited by 5
New and emerging treatments for osteoporosis
Clarke, B. L. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03541.x · Cited by 5
Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies
Clarke, B. L. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.04.006 · Cited by 5
Second meeting on bone quality, Abbaye des Vaux de Cernay, France, 19–20 June 2007: Cortical bone
(2008) · Osteoporosis International · doi:10.1007/s00198-008-0580-8 · Cited by 6
New agents for the treatment of osteoporosis
Martin, T. J., & Ng, K. W. (2007) · BoneKEy-Osteovision · doi:10.1138/20070279 · Cited by 5
Jiang, X., & Schnatz, P. F. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31827c44bd · Cited by 5
Ramchand, S. K., Tsai, J. N., Zhao, Y., Hershman, S. H., Tobert, D. G., Lee, H., Martins, J. D. S., David, N. L., Sassana-Khadka, G., Ryan, S., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf152 · Cited by 4
Zhu, Z., Huang, J.-Y., Wang, W., Liu, S., Zhang, H., Wang, Q., Fu, K., Ding, C., Wei, J. C., & Hunter, D. J. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.01.001 · Cited by 4
Behandlung der Osteoporose mit Denosumab
Ferrari, S. (2012) · Therapeutische Umschau · doi:10.1024/0040-5930/a000271 · Cited by 4
Current Knowledge, Drug-Based Therapeutic Options and Future Directions in Managing Osteoporosis
Moshiri, A., Sharifi, A. M., & Oryan, A. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-016-9207-3 · Cited by 6
Yavropoulou, M. P., Kasdagli, M., Makras, P., Diomatari, K.-M., Anastasilakis, A. D., Mitsikostas, D. D., Kassi, E. N., Sfikakis, P. P., & Kravvariti, E. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107874 · Cited by 4
Denosumab treatment of giant cell tumors in the spine induces woven bone formation
Birch, R., Eltit, F., Xie, D., Wang, Q., Dea, N., Fisher, C. G., Cox, M., Ng, T., Charest-Morin, R., & Wang, R. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf063 · Cited by 6
Denosumab: A New Therapy for Osteoporosis
Leonard, M. C., Lehmann, M. K., White, D. A., Wyman, M. J., Martin, A. F. S., Constantiner, M., & Kvancz, D. A. (2010) · Cited by 5
Gaffney‐Stomberg, E., MacArthur, M. R., & McClung, J. P. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_27 · Cited by 7
Seto, T., Yukata, K., Fujii, Z., Shibuya, M., Okazaki, T., Mihara, A., Uehara, K., Takemoto, K., Tsuji, S., Sakamoto, A., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf093 · Cited by 4
Spanish Menopause Society position statement: Use of denosumab in postmenopausal women
Cano, A., Silván, J. M., Estévez, A., Baró, F., Villero, J., Quereda, F., Ferrer, J., Mendoza, N., & Sánchez‐Borrego, R. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.06.011 · Cited by 4
The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women
Harris, K. B., Nealy, K. L., Jackson, D. J., & Thornton, P. L. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012442061 · Cited by 4
Current Controversies in Bisphosphonate Therapy
Kamath, A. F. (2009) · Orthopedics · doi:10.3928/01477447-20090527-03 · Cited by 4
Case Studies and Enrichment References
Bhagavan, N. V., & Ha, C. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-095461-2.00038-2 · Cited by 4
Lane, N. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00101-7 · Cited by 5
Joshi, M., Bisht, S., & Singh, M. F. (2019) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2019v11i10.34447 · Cited by 5
Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study
Lyu, H., Zhao, S. S., Li, J., Li, X., Wang, Y., Xie, D., Zeng, C., Lei, G., Wei, J., & Li, H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac262 · Cited by 5
Costa, A. G., Lewiecki, E. M., & Bilezikian, J. P. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch72 · Cited by 4
Self-citationOkawa, T., Okawa, M., & Koike, T. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01357-z · Cited by 4
The Role of the Immune System in the Development of Osteoporosis
Mödder, U. I., Riggs, B. L., & Khosla, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375670-1.10009-3 · Cited by 4
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Clarke, B. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70162-8 · Cited by 4
Malignancy-Associated Hypercalcemia and Medical Management
Horwitz, M. J., & Stewart, A. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00063-0 · Cited by 4
Translational research—preventing fractures with denosumab
Ebeling, P. R. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.234 · Cited by 4
Denosumab—a novel strategy to prevent structural joint damage in patients with RA?
Schett, G. A., & David, J. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0927 · Cited by 4
Diagnosis and Treatment of Osteoporosis
Thompson, S. M., & McGovern, P. G. (2011) · Postgraduate Obstetrics & Gynecology · doi:10.1097/01.pgo.0000403721.61250.ee · Cited by 4
Biology, Physiology, and Morphology of Bone
Schett, G. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00004-9 · Cited by 4
Variability of Denosumab densitometric response in postmenopausal osteoporosis
Laroche, M., Baradat, C., Ruyssen‐Witrand, A., & Degboé, Y. (2018) · Rheumatology International · doi:10.1007/s00296-018-3929-0 · Cited by 4
New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
Woźniczka, M., & Błaszczak-Świątkiewicz, K. (2021) · Molecules · doi:10.3390/molecules26216491 · Cited by 4
Gignac, G. A., Morris, M. J., & Hussain, M. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.033 · Cited by 5
A Step in the Journey of Denosumab From Bone-Targeted Therapy to Seed- and Soil-Targeted Therapy
Vignot, S., & Khayat, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7001 · Cited by 4
Akinpetide, G. O. (2014) · UA Campus Repository (The University of Arizona) · Cited by 4
Bowen, C. M., Demarest, K., Vilar, E., & Shah, P. D. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433576 · Cited by 5
Nouvelles cibles thérapeutiques dans l’ostéoporose
Roux, S. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2009.10.032 · Cited by 3
Repairing erosions in rheumatoid arthritis. A realistic goal
Silva, L., Castro, M. F., & Andreu, J. L. (2008) · Rheumatology · doi:10.1093/rheumatology/ken243 · Cited by 3
Efficacy and Safety of Osteoporosis Treatment
McClung, M. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-26757-9_5 · Cited by 3
Self-citationEndocrine and metabolic complications of advanced cancer
Ryan, R., & Casey, R. (2021) · doi:10.1093/med/9780198821328.003.0084 · Cited by 3
Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting
Kotecha, J., Fardeen, K. M., & Mirzazadeh, M. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001894 · Cited by 3
Yang, J. W., Park, Y., Lee, J. J., Kwok, S., Ju, J. H., Kim, W., & Park, S. H. (2025) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x251314712 · Cited by 3
New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis
Saito, K., & Tanaka, Y. (2009) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.32.149 · Cited by 3
Petranova, T., Sheytanov, I., Monov, S. V., Rashkov, R. K., & Kinov, P. S. (2013) · Biotechnology & Biotechnological Equipment · doi:10.5504/bbeq.2013.0045 · Cited by 3
Miyazawa, S., Nakamura, Y., Kosho, T., Kawame, H., Narumi, S., Hasegawa, T., Suzuki, T., & Kato, H. (2018) · Modern Rheumatology Case Reports · doi:10.1080/24725625.2018.1454573 · Cited by 3
Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis
Lewiecki, E. M. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_15 · Cited by 4
Self-citationDeformity Secondary to Vertebral Body Metastases
Pennington, Z. A., Ahmed, A. K., & Sciubba, D. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-42958-4_44 · Cited by 3
Vitamin D receptor gene polymorphism and hepatocellular carcinoma in chronic hepatitis C patients
Mosaad, H., Emam, E., Hamed, E. F., Demerdash, E. A. E., & Hussein, S. (2020) · Egyptian Liver Journal · doi:10.1186/s43066-020-00063-7 · Cited by 3
Jiang, Q., Zhang, F., Zhu, B., Zhang, H., Han, L., & Liu, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1294 · Cited by 4
Garnero, P., & Cremers, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00078-6 · Cited by 9
Bliuc, D., Tran, T. S., Chen, W., Alarkawi, D., Alajlouni, D. A., Blyth, F., MARCH, L. M., & Blank, R. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac669 · Cited by 3
de Winter, D. T. C., Neggers, S. J. C. M. M., van den Heuvel‐Eibrink, M. M., & van Atteveld, J. E. (2024) · Endocrine Connections · doi:10.1530/ec-24-0487 · Cited by 3
Inhibition of RANKL: a new approach to the treatment of osteoporosis
Doggrell, S. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1097 · Cited by 3
Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung
Trubrich, A., Kocijan, R., Muschitz, C., & Resch, H. (2011) · Osteologie/Osteology · doi:10.1055/s-0037-1619994 · Cited by 3
Management of Osteoporotic Patients with Distal Radial Fractures
Patel, S. P., & Rozental, T. D. (2014) · JBJS Reviews · doi:10.2106/jbjs.rvw.m.00113 · Cited by 3
Pundole, X., Kebriaei, P., & Lu, H. (2014) · IBMS BoneKEy · doi:10.1038/bonekey.2014.58 · Cited by 3
Therapeutic advances in the treatment of osteoporosis
Mathoo, J., Becker, L., Kumbhare, D. A., & Adachi, J. D. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.3.277 · Cited by 3
New Therapies for Osteoporosis
Hegge, K. A., Fornoff, A., Gutierres, S. L., & Haack, S. L. (2008) · Journal of Pharmacy Practice · doi:10.1177/0897190008322247 · Cited by 6
Clar, H., Renner, W., Krippl, P., Leithner, A., Gruber, G., Langsenlehner, T., Hofmann, G., Yazdani‐Biuki, B., Clar, V., Windhager, R., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9863-6 · Cited by 3
Dénosumab : traitement à vie de l’ostéoporose ?
Laroche, M. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2015.12.010 · Cited by 3
Gaffney‐Stomberg, E., MacArthur, M. R., & McClung, J. P. (2016) · Exposure and Health · doi:10.1007/978-94-007-7745-3_27-1 · Cited by 3
An Endocrinologist's Perspective
Lebovitz, H. E. (2013) · Cited by 3
Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises
Sledge, G. W., Jotwani, A. C., & Mina, L. A. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.04.005 · Cited by 4
Systemic therapy and novel agents for metastatic castration resistant prostate cancer
Fleming, M. T., Sonpavde, G., Kondagunta, G. V., Galsky, M. D., Hutson, T. E., & Sternberg, C. N. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2008.10.002 · Cited by 4
Lattouf, J., Fadlallah, H., & Fred Saad, C. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0045-9 · Cited by 3
[Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
Czekuć-Kryśkiewicz, E., & Lorenc, R. S. (2009) · PubMed · Cited by 3
Mechanism of Action for Therapeutic Antibodies
Zhou, Y., & Marks, J. D. (2016) · Wiley eBooks · doi:10.1002/9781118940648.ch3 · Cited by 3
Deal, C. L., & Abelson, A. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00201-1 · Cited by 3
Lane, N. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00101-8 · Cited by 3
Monoclonal Antibodies as Therapeutic Agents
Khan, M. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-77976-8_5 · Cited by 4
Clarke, B. L. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.04.023 · Cited by 3
Endocrine and metabolic complications of advanced cancer
Bower, M., Robinson, L. A., & Cox, S. (2015) · doi:10.1093/med/9780199656097.003.0142 · Cited by 3
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.